Isomorphic Labs Expands Research Collaboration with Novartis
Deal News | Mar 07, 2025 | Goodwin
Isomorphic Labs, a company specializing in AI-driven drug discovery and backed by Alphabet, has expanded its strategic research collaboration with Novartis, a leading pharmaceutical company. The move will allow Isomorphic Labs and Novartis to incorporate up to three additional research programs under the same financial terms as the original agreement, furthering their commitment to advancing medical breakthroughs through AI. The advisory role for this strategic expansion was held by Goodwin, with the deal led by Noelle Dubiansky, Beth Withers, and Katerina Stavrianidis. This collaboration aims to harness the potential of artificial intelligence to revolutionize drug discovery, building on Isomorphic Labs' foundation established by AI pioneer Sir Demis Hassabis.
Sectors
- Life Sciences
- Artificial Intelligence
- Pharmaceuticals
Geography
- Global – Both Isomorphic Labs and Novartis have a global presence in the fields of AI and pharmaceuticals, indicating the worldwide scope of their research collaboration.
Industry
- Life Sciences – The collaboration involves strategic research in drug discovery, a core aspect of the life sciences sector, particularly leveraging AI-technology for medical advancements.
- Artificial Intelligence – Isomorphic Labs utilizes AI (originating from AlphaFold 2) to drive innovation in drug discovery, marking significant intersections between AI technology and healthcare solutions.
- Pharmaceuticals – Novartis, a key participant, is a major player in pharmaceuticals, and their involvement signifies the sector's interest in adopting cutting-edge AI for drug development.
Financials
- Same financial terms as the original agreement – The expansion includes up to three additional research programs without altering the original financial structure.
Participants
| Name | Role | Type | Description |
|---|---|---|---|
| Isomorphic Labs | Target Company | Company | A company founded in 2021, specializing in AI-driven drug discovery and backed by Alphabet. |
| Novartis | Collaboration Partner | Company | A leading global pharmaceutical company partnering with Isomorphic Labs to use AI for drug discovery. |
| Goodwin | Legal Advisor | Company | The law firm that advised on the expansion of the strategic collaboration between Isomorphic Labs and Novartis. |
| Sir Demis Hassabis | Leader | Person | AI pioneer and leader of Isomorphic Labs, playing a crucial role in its foundation and strategic direction. |
| Alphabet | Investor | Company | The parent company of Google, providing backing to Isomorphic Labs for its AI innovations. |
| Noelle Dubiansky | Deal Team Leader | Person | Led the deal team at Goodwin for the Isomorphic Labs and Novartis collaboration expansion. |
| Beth Withers | Deal Team Member | Person | A member of the deal team at Goodwin involved in advising Isomorphic Labs. |
| Katerina Stavrianidis | Deal Team Member | Person | A member of the deal team at Goodwin involved in advising Isomorphic Labs. |